Clinical Trials
10 trialsNCT06240741 2026-02-03
A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan
Novartis
Phase 3 Completed
NCT03098589 2025-03-30
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
Celgene
Completed
NCT02921828 2022-07-05
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
Celgene
Completed
NCT02921802 2022-06-14
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
Celgene
Completed
NCT02922543 2022-06-14
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
Celgene
Completed
NCT03406325 2020-04-09
Mast Cell Activation Test in Allergic Disease
Hong Kong Sanatorium & Hospital
Completed
NCT03858738 2019-03-04
A Pilot Study on Use of Liquid Crystal Contact Thermography to Detect Early Breast Cancer
Braster S.A.
Completed
NCT01033123 2016-03-17
A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
Sanofi
Phase 2 Completed
NCT01033292 2016-03-17
A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Sanofi
Phase 2 Completed
NCT00116610 2009-01-21
Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer
Poniard Pharmaceuticals
Phase 2 Completed